56 completed, 10 recruiting, 7 terminated, 6 unknown. 84 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 84 | Completed 56, Recruiting 10, Terminated 7, Unknown 6, Active not recruiting 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 2 | 13 | Completed 8, Recruiting 2, Unknown 2, Withdrawn 1 |
Follow Parathyroid Diseases: new trials by email Literature Review of Parathyroid Diseases trials Research Report on Parathyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis PLS240, Standard of Care - Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism | Phase 3 | Not yet recruiting | Pathalys Pharma | 56 | 2026-10-30 | 2026-10-22 |
| Efficacy, Safety, and Tolerability of Encaleret in Participants With Chronic Hypoparathyroidism Encaleret, Placebo - Hypoparathyroidism, Chronic Hypoparathyroidism | Phase 3 | Recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 160 | 2026-08-31 | 2026-11-04 |
| A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism Canvuparatide, Placebo - Hypoparathyroidism | Phase 3 | Recruiting | MBX Biosciences | 160 | 2026-08-26 | 2026-10-29 |
| A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism Palopegteriparatide Experimental Arm, Palopegteriparatide Control Arm - Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Recruiting | Ascendis Pharma Bone Diseases A/S | 36 | 2026-05-07 | 2026-11-05 |
| A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism Palopegteriparatide - Hypoparathyroidism | Phase 3 | Recruiting | Ascendis Pharma A/S | 12 | 2026-04-22 | 2026-07-28 |
| Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors 18F-FCH, NeuroEXPLORER - Primary Hyperparathyroidism, Parathyroid Cancer | Phase 2 / Phase 3 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 193 | 2026-04-16 | 2026-10-29 |
| Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism MT1013, Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Recruiting | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 424 | 2025-09-30 | 2026-11-05 |
| The Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 498 | 2024-06-14 | 2025-12-12 |
| 99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT 18Fluorocholine - Parathyroid Adenoma | Phase 2 / Phase 3 | Recruiting | Andrei Iagaru | 100 | 2023-09-27 | 2026-06-24 |
| Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism eneboparatide, Placebo - Chronic Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 165 | 2023-06-07 | 2025-09-29 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Completed | Pathalys Pharma | 362 | 2023-04-28 | 2025-09-09 |
| Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism CTAP101, Placebo - Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Phase 3 | Terminated | OPKO Health, Inc. | 2 | 2023-01-31 | 2025-07-25 |
| Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Encaleret, Standard of Care - Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Active not recruiting | Calcilytix Therapeutics, Inc., a BridgeBio company | 67 | 2023-01-06 | 2026-07-29 |
| A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Secondary Hyperparathyroidism Paricalcitol, Placebo - Secondary Hyperparathyroidism | Phase 3 | Unknown | Chengdu Suncadia Medicine Co., Ltd. | 84 | 2022-02-01 | 2022-02-10 |
| PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism TransCon PTH, placebo - Hypoparathyroidism, Parathyroid Hormone Deficiency | Phase 3 | Completed | Visen Pharmaceuticals (Shanghai) Co., Ltd. | 81 | 2021-07-28 | 2026-01-16 |
| 18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas 18F-Fluorocholine, Positron emission tomography (PET) - Hyperparathyroidism, Primary | Phase 3 | Completed | Thomas Hope | 139 | 2021-06-30 | 2026-04-29 |
| Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy ICG, Control group - Thyroid Diseases | Phase 3 | Recruiting | University Hospital, Brest | 242 | 2021-06-22 | 2026-03-19 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Teriparatide - Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 3 | Completed | Saint Petersburg State University, Russia | 20 | 2021-03-01 | 2022-11-10 |
| A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism TransCon PTH, Placebo - Hypoparathyroidism, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Bone Diseases A/S | 84 | 2021-02-16 | 2026-07-07 |
Showing 20 of 84. Sign in to see all of them.
Hyperparathyroidism, Secondary (44) · Renal Insufficiency, Chronic (24) · Hypoparathyroidism (19) · Hyperparathyroidism (14) · Kidney Failure, Chronic (11) · Hyperparathyroidism, Primary (10) · Hypocalcemia (8) · Vitamin D Deficiency (8) · Kidney Diseases (6) · Parathyroid Neoplasms (6) · Hypercalcemia (5) · Endocrine System Diseases (4) · Renal Insufficiency (4) · Chronic Kidney Disease-Mineral and Bone Disorder (3)
Endocrine System Diseases (80) · Hyperparathyroidism (49) · Pathological Conditions, Signs and Symptoms (37) · Female Urogenital Diseases (35) · Female Urogenital Diseases and Pregnancy Complications (35) · Male Urogenital Diseases (35) · Urogenital Diseases (35) · Urologic Diseases (35) · Disease Attributes (34) · Pathologic Processes (34) · Chronic Disease (33) · Kidney Diseases (29) · Renal Insufficiency (26) · Nutritional and Metabolic Diseases (23)
Cinacalcet (20) · etelcalcetide hydrochloride (9) · paricalcitol (8) · Standard of Care (6) · Parathyroid Hormone (4) · Calcifediol (3) · Cholecalciferol (3) · fluorocholine (3) · Magnetic Resonance Spectroscopy (2) · Sodium Chloride (2) · Sugars (2) · Teriparatide (2) · 1 alpha-hydroxyergocalciferol (1) · Amiloride (1) · Calcitriol (1)
Amgen (19) · Kyowa Kirin Co., Ltd. (6) · Shire (5) · OPKO Health, Inc. (3) · Pathalys Pharma (3) · AbbVie (prior sponsor, Abbott) (2) · Ascendis Pharma Bone Diseases A/S (2) · Calcilytix Therapeutics, Inc., a BridgeBio company (2) · Columbia University (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · OPKO IP Holdings II, Inc. (2) · Sanwa Kagaku Kenkyusho Co., Ltd. (2) · Thomas Hope (2) · AbbVie (1) · Abbott (1)
United States (44) · France (15) · Hungary (15) · Poland (15) · Canada (14) · Italy (14) · Germany (12) · Spain (12) · Belgium (11) · Japan (11) · Russia (11) · Czechia (9) · Denmark (9) · Australia (8) · China (8)
Joel Melnick, MD (4) · John P Bilezikian, MD (3) · Thomas Hope, MD (2) · Akhtar Ashfaq, MD (1) · Anand Vaidya, MD MMSc (1) · Andrei Iagaru, MD (1) · Ann Eldred, MD (1) · David J Whellan, MD MHS (1) · Enrico E. Verrina, MD (1)
PMID 36018496, PMID 32738041, PMID 35696069, PMID 35974422, PMID 40576086, PMID 11576947, PMID 15689407, PMID 15828905, PMID 16105056, PMID 17556697, PMID 18793528, PMID 19480654, PMID 20435429, PMID 22202993, PMID 23222688, PMID 24128439, PMID 24622413, PMID 25029424, PMID 25404192, PMID 25685872, PMID 25710802, PMID 25851955, PMID 25887067, PMID 25950238, PMID 26059012, PMID 26684150, PMID 26951967, PMID 27080930, PMID 28332096, PMID 28942334, PMID 29099947, PMID 29525393, PMID 29779023, PMID 29972871, PMID 30859218, PMID 30955188, PMID 31369089, PMID 32333877, PMID 33283264, PMID 33413316, PMID 34003226, PMID 35018442, PMID 35176038, PMID 36512619, PMID 37696667, PMID 38691316, PMID 38741607, PMID 38900416, PMID 39136801, PMID 39969301
2017 (2), 2023 (2), 2008 (1), 2009 (1), 2014 (1), 2016 (1), M01RR000042 (1), P50AR054086 (1), R01DK069350 (1), R01DK084986 (1)